LLY

Over a two-week horizon, Eli Lilly exhibits a neutral consolidation pattern following the recent 11% pullback from highs. The stock is trading between well-defined support ($1125.86) and resistance ($1206.28) levels, with moving averages converged around $1176. The medium-term outlook remains supported by strong fundamentals: 56% Q1 revenue growth, dominant GLP-1 market position, and retatrutide pipeline catalyst. Price target of $1185.75 represents a 3.2% recovery from current levels. The high P/E ratio (68.9x) suggests limited upside surprise potential, but the pullback provides a reasonable entry point for investors with a 2-3 week holding period.

• Two-week timeframe shows consolidation pattern between support and resistance
• SMA 20 and SMA 50 nearly aligned at ~1176, indicating equilibrium
• Retatrutide pipeline catalyst (projected $3.8B revenue by 2030) provides medium-term support
• Current valuation pullback creates attractive risk/reward for 2-week holding period
• Blockbuster GLP-1 franchise (Mounjaro/Zepbound) provides revenue stability

• Elevated P/E ratio of 68.9x leaves limited margin for disappointment
• Potential for further consolidation or breakdown below $1125.86
• Competitive pressure from Novo Nordisk and other GLP-1 players
• Regulatory uncertainty around obesity drug market expansion

Actionable Items

• Accumulate on dips toward $1130-1140 support zone
• Target resistance breakout above $1206.28 for continuation
• Monitor earnings announcements and pipeline updates
• Consider 2-week call spreads for defined risk exposure

News Sentiment